Lacey Elizabeth Dobrolecki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lacey Elizabeth Dobrolecki has a total of 371 co-authors. Here are the top co-authors by number of shared publications:
- Michael T. Lewis
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas
135 shared publications - Shunqiang Li
Department of Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri
117 shared publications - Nicholas Mitsiades
Division of Hematology and Oncology, University of California Davis, Davis, California
96 shared publications - John D. Landua
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas
95 shared publications - Alana L. Welm
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
92 shared publications - Bryan E. Welm
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
92 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF18
LIG1 Loss in TP53 -mutant Triple-Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP–ATR Inhibitor Combinations
Proteogenomic analyses have identified an association between LIG1 (DNA ligase I) loss and chemotherapy resistance in a subset of triple-negative breast cancer (TNBC) enriched for TP53 mutations. In this study, we demonstrate that co-occurrence of TP53 mutations and LIG1 loss is associated with upregulated DNA damage repair (DDR) activity, including homologous recombination (HR), likely contributing to reduced platinum sensitivity. Unbiased genetic and monotherapy drug screens identified poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) as a potential treatment for LIG1-depleted tumors; however, the increase in sensitivity was modest and lower than that observed in TNBC models with HR deficiency. Subsequently, a screen of PARP inhibition in combination with each of 120 clinically relevant DDR inhibitors revealed that PARPi sensitivity in LIG1-loss cells was significantly enhanced by the addition of an ATR inhibitor. Olaparib and ceralasertib demonstrated synergistic cytotoxicity in LIG1-loss cell line models; the combination significantly reduced tumor volume in a LIG1-low patient-derived xenograft (PDX )model compared with either monotherapy and showed greater ex vivo cytotoxicity in a LIG1-low PDX organoid model versus a LIG1-high control. Hence, this study highlights LIG1 status as a stratification factor for ongoing and future clinical trials of DDR-targeted combinations in TNBCs.
- 3 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF18
Open AccessLIG1 Loss in TP53 -mutant Triple-Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP–ATR Inhibitor Combinations
Proteogenomic analyses have identified an association between LIG1 (DNA ligase I) loss and chemotherapy resistance in a subset of triple-negative breast cancer (TNBC) enriched for TP53 mutations. In this study, we demonstrate that co-occurrence of TP53 mutations and LIG1 loss is associated with upregulated DNA damage repair (DDR) activity, including homologous recombination (HR), likely contributing to reduced platinum sensitivity. Unbiased genetic and monotherapy drug screens identified poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) as a potential treatment for LIG1-depleted tumors; however, the increase in sensitivity was modest and lower than that observed in TNBC models with HR deficiency. Subsequently, a screen of PARP inhibition in combination with each of 120 clinically relevant DDR inhibitors revealed that PARPi sensitivity in LIG1-loss cells was significantly enhanced by the addition of an ATR inhibitor. Olaparib and ceralasertib demonstrated synergistic cytotoxicity in LIG1-loss cell line models; the combination significantly reduced tumor volume in a LIG1-low patient-derived xenograft (PDX )model compared with either monotherapy and showed greater ex vivo cytotoxicity in a LIG1-low PDX organoid model versus a LIG1-high control. Hence, this study highlights LIG1 status as a stratification factor for ongoing and future clinical trials of DDR-targeted combinations in TNBCs.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Diffuse mesothelioma is a rare but highly aggressive and treatment-resistant neoplasm with low survival rates. Effective therapeutic strategies are limited, and resistance to treatment is a major obstacle. Myeloid cell leukemia (MCL)-1 and B-cell leukemia (BCL)-xL are antiapoptotic B-cell lymphoma 2 (Bcl-2) family proteins that block cell-intrinsic apoptosis through interactions on the mitochondrial outer membrane which contribute to therapeutic resistance. We investigated whether B-cell homology domain3 profiles were consistent between intra-patient fresh tumor sample, patient-derived cells, and patient-derived xenografts (PDX) by B-cell homology domain-3 profiling; we observed striking consistency which enabled cross-model comparisons. Next, we co-targeted BCL-xl and MCL-1 and noted that the combination synergistically reduced cell viability and increased apoptosis. Mechanistically, BCL-xL inhibition affected the cells through both the canonical and the emerging noncanonical apoptotic pathways. BCL-xL induced mitochondrial depolarization which resulted in MCL-1 cellular dependency, rendering cells highly sensitive to MCL-1 inhibition. Next, we co-targeted BCL-xL and MCL-1 in vivo which induced synthetic lethality in PDX models within hours, implying that this approach is not a safe strategy for clinical development. However, targeting MCL-1, which exerts its antiapoptotic activity without non-apoptotic on-target effects, decreased the mitochondrial threshold for apoptosis and enhanced chemosensitivity without toxicity in PDX models. Our findings suggest that targeting the mitochondria via MCL-1 enhances the efficacy of chemotherapy but co-targeting two proteins in the Bcl-2 pathways results in synergistic lethality. These results will help define a safe clinical strategy to utilize Bcl-2–targeted therapy to undermine therapeutic resistance in patients with diffuse mesothelioma.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Diffuse mesothelioma is a rare but highly aggressive and treatment-resistant neoplasm with low survival rates. Effective therapeutic strategies are limited, and resistance to treatment is a major obstacle. Myeloid cell leukemia (MCL)-1 and B-cell leukemia (BCL)-xL are antiapoptotic B-cell lymphoma 2 (Bcl-2) family proteins that block cell-intrinsic apoptosis through interactions on the mitochondrial outer membrane which contribute to therapeutic resistance. We investigated whether B-cell homology domain3 profiles were consistent between intra-patient fresh tumor sample, patient-derived cells, and patient-derived xenografts (PDX) by B-cell homology domain-3 profiling; we observed striking consistency which enabled cross-model comparisons. Next, we co-targeted BCL-xl and MCL-1 and noted that the combination synergistically reduced cell viability and increased apoptosis. Mechanistically, BCL-xL inhibition affected the cells through both the canonical and the emerging noncanonical apoptotic pathways. BCL-xL induced mitochondrial depolarization which resulted in MCL-1 cellular dependency, rendering cells highly sensitive to MCL-1 inhibition. Next, we co-targeted BCL-xL and MCL-1 in vivo which induced synthetic lethality in PDX models within hours, implying that this approach is not a safe strategy for clinical development. However, targeting MCL-1, which exerts its antiapoptotic activity without non-apoptotic on-target effects, decreased the mitochondrial threshold for apoptosis and enhanced chemosensitivity without toxicity in PDX models. Our findings suggest that targeting the mitochondria via MCL-1 enhances the efficacy of chemotherapy but co-targeting two proteins in the Bcl-2 pathways results in synergistic lethality. These results will help define a safe clinical strategy to utilize Bcl-2–targeted therapy to undermine therapeutic resistance in patients with diffuse mesothelioma.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
The BH3 profiles of DM patients showed similar activities in the tumor samples as well as the corresponding tumor sample derived cells.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
The BH3 profiles of DM patients showed similar activities in the tumor samples as well as the corresponding tumor sample derived cells.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Co-targeting MCL-1 and BCL-xL synergistically increase cell death through the intrinsic mitochondrial apoptotic pathway in PDC.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Co-targeting MCL-1 and BCL-xL synergistically increase cell death through the intrinsic mitochondrial apoptotic pathway in PDC.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
BCL-xL inhibition does not change mitochondrial fusion and fission related proteins.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
BCL-xL inhibition does not change mitochondrial fusion and fission related proteins.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Materials & Methods from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Supplementary Materials & Methods
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials & Methods from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Supplementary Materials & Methods
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Pathology evaluation of H&E slides for MPM188 tissue from the patient (Pt) and the PDX
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Pathology evaluation of H&E slides for MPM188 tissue from the patient (Pt) and the PDX
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Supplementary Table S4 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Supplementary Table S4 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Characterization of DM patient derived cell lines (PDC) and in vitro growth features.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Characterization of DM patient derived cell lines (PDC) and in vitro growth features.